Candel Therapeutics, Inc. income statement

In fiscal 2022, Candel Therapeutics, Inc. reported revenue of $125,000, up 0.0% on the year before, operating income of −$34.7m (a -27777.6% margin) and net income of −$18.8m, or −$0.65 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Candel Therapeutics, Inc.: income statement, annual
Fiscal year	2020Dec 2020	2021Dec 2021	2022Dec 2022
Revenue	0	0	0
Research and development	9	15	21
General and administrative	5	11	14
Operating income	−14	−26	−35
Interest expense	—	—	2
Income tax	—	0	0
Net income	−18	−36	−19
Diluted EPS	−$1.52	−$1.91	−$0.65
Diluted shares (average)	12m	19m	29m
EBITDA	−14	−25	−34

US$ millions unless shown otherwise. Fiscal quarters.

Candel Therapeutics, Inc.: income statement, quarterly
Quarter	2021 Q1Mar 2021	2021 Q2Jun 2021	2021 Q3Sept 2021	2021 Q4Dec 2021	2022 Q1Mar 2022	2022 Q2Jun 2022	2022 Q3Sept 2022	2022 Q4Dec 2022
Revenue	0	0	0	0	0	0	0	0
Research and development	3	3	5	4	5	5	5	5
General and administrative	2	2	3	4	4	4	4	3
Operating income	−5	−5	−8	−8	−9	−9	−9	−8
Interest expense	—	—	—	—	—	0	1	1
Net interest income	—	—	—	—	−0	—	—	—
Income tax	—	—	0	0	0	0	0	0
Net income	−4	−17	−16	2	−1	−4	−9	−5
Diluted EPS	−$0.19	−$0.73	−$0.69	$0.51	−$0.03	−$0.14	−$0.30	−$0.17
EBITDA	−5	−5	−8	−8	−9	−9	−9	−8

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Candel Therapeutics, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Candel Therapeutics, Inc.